"シオノギ製薬" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonShionogi completes acquisition of rights to ALS drug Radicava - ALS News Today
Shionogi completes acquisition of rights to ALS drug Radicava ALS News Today
Shionogi lands $482M contract as US targets superbugs, supply chain gaps - FirstWord Pharma
Shionogi lands $482M contract as US targets superbugs, supply chain gaps FirstWord Pharma
Shionogi wins BARDA contract - thepharmaletter.com
Shionogi wins BARDA contract thepharmaletter.com
Shionogi's $482M U.S. Fetroja Manufacturing Push: Cash Catalyst vs. Execution Overhang - Bitget
Shionogi's $482M U.S. Fetroja Manufacturing Push: Cash Catalyst vs. Execution Overhang Bitget
Shionogi & Co - Receives Contract With U.S. Government Through Barda's Project Bioshield To Enhan...
Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance Nati...
Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance Nationa PharmiWeb.com
Shionogi Enters $2.5 Billion Agreement to Acquire All Rights to Radicava - Pharmaceutical Executive
Shionogi Enters $2.5 Billion Agreement to Acquire All Rights to Radicava Pharmaceutical Executive
How Investors May Respond To Shionogi (TSE:4507) Acquiring Full RADICAVA Rights And Expanding In ...
How Investors May Respond To Shionogi (TSE:4507) Acquiring Full RADICAVA Rights And Expanding In Rare Disease simplywall.st
Shionogi completes $2.5B deal for ALS drug Radicava rights - NJBIZ
Shionogi completes $2.5B deal for ALS drug Radicava rights NJBIZ
Shionogi: $2.5 Billion Acquisition Of RADICAVA Establishes Rare Disease Platform - Pulse 2.0
Shionogi: $2.5 Billion Acquisition Of RADICAVA Establishes Rare Disease Platform Pulse 2.0
Shionogi & Co., Ltd. (4507.T) stock price, news, quote and history - Yahoo Finance UK
Shionogi & Co., Ltd. (4507.T) stock price, news, quote and history Yahoo Finance UK
Pharma Pulse: Shionogi’s $2.5B Radicava Acquisition and the Industry Monitors U.S.-Iran Conflict ...
Pharma Pulse: Shionogi’s $2.5B Radicava Acquisition and the Industry Monitors U.S.-Iran Conflict for Supply Disruptions Pharmaceutical Commerce
Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone) - Business Wire
Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone) Business Wire
Apnimed Announces Strategic Monetization of Shionogi-Apnimed Sleep Science (SASS) Joint Venture S...
Shionogi enrols first patients in Esprit trial for Pompe disease - Clinical Trials Arena
Shionogi enrols first patients in Esprit trial for Pompe disease Clinical Trials Arena
Shionogi pays Apnimed $100M for joint venture to awaken sleep disorder dream - fiercebiotech.com
Shionogi pays Apnimed $100M for joint venture to awaken sleep disorder dream fiercebiotech.com
Shionogi & Co Ltd stock: Why this pharma giant merits your watchlist now - ad-hoc-news.de
Shionogi & Co Ltd stock: Why this pharma giant merits your watchlist now ad-hoc-news.de
Shionogi buys out Apnimed's stake in sleep-focused joint venture for $100M - FirstWord Pharma
Shionogi buys out Apnimed's stake in sleep-focused joint venture for $100M FirstWord Pharma
Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s ...
Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science Pharmaceutical Executive
Tanabe Pharma America Announces Finalization of RADICAVA (edaravone) Transfer to Shionogi - Block...
Tanabe Pharma America Announces Finalization of RADICAVA (edaravone) Transfer to Shionogi Block Island Times
A Look At Shionogi (TSE:4507) Valuation After Recent Share Price Momentum - Yahoo Finance
A Look At Shionogi (TSE:4507) Valuation After Recent Share Price Momentum Yahoo Finance
Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-O...
Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease Business Wire
ESCMID Global 2026: Shionogi Presents New Real-World Data Highlighting Clinical Effectiveness of ...
ESCMID Global 2026: Shionogi Presents New Real-World Data Highlighting Clinical Effectiveness of Fet PharmiWeb.com
Shionogi & Co: Acquisition Of All Rights To Radicava (Edaravone) Is Expected To Be Immediately Ac...
The Power to Create Medicines That Reach Patients—Passing SHIONOGI’s Baton of Innovation to the N...
The Power to Create Medicines That Reach Patients—Passing SHIONOGI’s Baton of Innovation to the Next Generation Shionogi Inc.
Shionogi to buy out Apnimed stake in JV - thepharmaletter.com
Shionogi to buy out Apnimed stake in JV thepharmaletter.com
Shionogi Seals $2.5 Billion RADICAVA Deal to Build Rare Disease Franchise - TipRanks
Shionogi Seals $2.5 Billion RADICAVA Deal to Build Rare Disease Franchise TipRanks
Assessing Shionogi (TSE:4507) Valuation After Strong Nine‑Month Earnings And Share Price Momentum...
Assessing Shionogi (TSE:4507) Valuation After Strong Nine‑Month Earnings And Share Price Momentum Yahoo Finance
GSK, Pfizer and Shionogi finalize changes to ViiV Healthcare ownership - Investing.com
GSK, Pfizer and Shionogi finalize changes to ViiV Healthcare ownership Investing.com
Why Shionogi (TSE:4507) Is Up 6.2% After Profit Growth Outpaced Sales In Latest Results – And Wha...
Why Shionogi (TSE:4507) Is Up 6.2% After Profit Growth Outpaced Sales In Latest Results – And What's Next Yahoo Finance
Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up - Pharmaceutical Technology
Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up Pharmaceutical Technology
Shionogi shells out $2.5B for Mitsubishi Tanabe's ALS drug - FirstWord Pharma
Shionogi shells out $2.5B for Mitsubishi Tanabe's ALS drug FirstWord Pharma
GSK and Shionogi Reshape ViiV Healthcare Ownership as Pfizer Exits HIV Venture - TipRanks
GSK and Shionogi Reshape ViiV Healthcare Ownership as Pfizer Exits HIV Venture TipRanks
Shionogi moves to acquire global rights to Radicava for ALS - ALS News Today
Shionogi moves to acquire global rights to Radicava for ALS ALS News Today
Shionogi Acquires $2.1 Billion ViiV Healthcare Shareholdings from Pfizer - Pharmaceutical Executive
Shionogi Acquires $2.1 Billion ViiV Healthcare Shareholdings from Pfizer Pharmaceutical Executive
Shionogi MDD drug Zurzuvae launched in Japan - thepharmaletter.com
Shionogi MDD drug Zurzuvae launched in Japan thepharmaletter.com
Shionogi boosts ViiV Healthcare stake as Pfizer exits joint HIV venture - TipRanks
Shionogi boosts ViiV Healthcare stake as Pfizer exits joint HIV venture TipRanks
Shionogi in Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® and IV RADI...
Shionogi in Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® and IV RADICAVA Cleary Gottlieb
Shionogi Invests $2.1 Billion to Raise ViiV Healthcare Stake - Bloomberg.com
Shionogi Invests $2.1 Billion to Raise ViiV Healthcare Stake Bloomberg.com
Pfizer exits ViiV, selling stake to Shionogi in $2.1B deal - FirstWord Pharma
Pfizer exits ViiV, selling stake to Shionogi in $2.1B deal FirstWord Pharma
Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Custom...
[Press release] GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding - Europ...
[Press release] GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding European AIDS Treatment Group
ALS med Radicava to change hands as Shionogi inks $2.5B buyout - Fierce Pharma
ALS med Radicava to change hands as Shionogi inks $2.5B buyout Fierce Pharma
Pfizer to Exit ViiV Healthcare as GSK and Shionogi Reshape Ownership - Yahoo Finance
Pfizer to Exit ViiV Healthcare as GSK and Shionogi Reshape Ownership Yahoo Finance
Shionogi Completes $2.5 Billion RADICAVA Rights Acquisition - marketscreener.com
Shionogi Completes $2.5 Billion RADICAVA Rights Acquisition marketscreener.com
Shionogi Increasing Stake in ViiV Healthcare for $2.1 Bn; Pfizer Exits the HIV JV - DCAT Value Ch...
Shionogi Increasing Stake in ViiV Healthcare for $2.1 Bn; Pfizer Exits the HIV JV DCAT Value Chain Insights
Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake - Reuters
Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake Reuters
Shionogi (TSE:4507): Evaluating Valuation After a Strong Year-to-Date Share Price Gain - Yahoo Fi...
Shionogi (TSE:4507): Evaluating Valuation After a Strong Year-to-Date Share Price Gain Yahoo Finance
Shionogi Secures ¥300 Billion Bridge Loan for Expanded ViiV Healthcare Stake - The Globe and Mail
Shionogi Secures ¥300 Billion Bridge Loan for Expanded ViiV Healthcare Stake The Globe and Mail
Shionogi Expands Rare Disease Presence with Planned Acquisition of Global Rights to Tanabe Pharma...
Tanabe Pharma America Announces Finalization of RADICAVA (edaravone) Transfer to Shionogi - Floyd...
Tanabe Pharma America Announces Finalization of RADICAVA (edaravone) Transfer to Shionogi Floyd County Times
Fierce Pharma Asia—China biotech deal spree rolls on; Shionogi buys Tanabe's ALS business - Fierc...
Fierce Pharma Asia—China biotech deal spree rolls on; Shionogi buys Tanabe's ALS business Fierce Pharma
FDA Accepts Shionogi’s NDA for Ensitrelvir Oral Antiviral in COVID-19 Postexposure Prevention - C...
FDA Accepts Shionogi’s NDA for Ensitrelvir Oral Antiviral in COVID-19 Postexposure Prevention Contagion Live
Shionogi to buy Jersey City pharma for $2.5B - NJBIZ
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Up - What's Next? - MarketBeat
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Up - What's Next? MarketBeat
Results: Shionogi & Co., Ltd. Beat Earnings Expectations And Analysts Now Have New Forecasts - si...
Results: Shionogi & Co., Ltd. Beat Earnings Expectations And Analysts Now Have New Forecasts simplywall.st
Pfizer sells its stake in GSK's ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused ...
Pfizer sells its stake in GSK's ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused company Fierce Pharma
Pfizer, GSK, Shionogi sponsor London run of musical about antimicrobial resistance - Fierce Pharma
Pfizer, GSK, Shionogi sponsor London run of musical about antimicrobial resistance Fierce Pharma
Shionogi to acquire ALS medications from Tanabe - thepharmaletter.com
Shionogi to acquire ALS medications from Tanabe thepharmaletter.com
Shionogi & Co: acquisition of all rights to Radicava (edaravone) is expected to be immediately ac...
Asia roundup: Shionogi ups Viiv stake, Fosun spinoff plans, more - BioWorld News
Asia roundup: Shionogi ups Viiv stake, Fosun spinoff plans, more BioWorld News
GSK's Partner Shionogi Acquires Pfizer's Stake in ViiV Healthcare for About $2.13 Billion - Moomoo
GSK's Partner Shionogi Acquires Pfizer's Stake in ViiV Healthcare for About $2.13 Billion Moomoo
Shionogi’s Short-Term Loan Gamble: How the 2027 Refinancing Hurdle May Undermine Its ViiV Strateg...
Shionogi’s Short-Term Loan Gamble: How the 2027 Refinancing Hurdle May Undermine Its ViiV Strategy Bitget
FDA Accepts Shionogi’s Ensitrelvir NDA for COVID PEP - Infectious Disease Special Edition
FDA Accepts Shionogi’s Ensitrelvir NDA for COVID PEP Infectious Disease Special Edition
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact - BioWorld News
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact BioWorld News
Enrollment Update - Shionogi Inc.
Enrollment Update Shionogi Inc.
Tanabe Pharma America Announces Finalization of RADICAVA (Edaravone) Transfer to Shionogi - Moomoo
Tanabe Pharma America Announces Finalization of RADICAVA (Edaravone) Transfer to Shionogi Moomoo
Shionogi Eyes US Plant to Boost Antibiotic Production Amid Tariffs Challenge - JAPAN Forward
Shionogi Eyes US Plant to Boost Antibiotic Production Amid Tariffs Challenge JAPAN Forward
GSK, Pfizer, And Shionogi Agree On ViiV Healthcare Shareholding Changes - TradingView
GSK, Pfizer, And Shionogi Agree On ViiV Healthcare Shareholding Changes TradingView
Shionogi expands stake in ViiV Healthcare following Pfizer’s exit, GSK retains majority share - B...
Shionogi expands stake in ViiV Healthcare following Pfizer’s exit, GSK retains majority share BioXconomy
Pfizer sells ViiV stake to Shionogi - thepharmaletter.com
Pfizer sells ViiV stake to Shionogi thepharmaletter.com
Shionogi & Co Ltd - to acquire 50% stake in Shionogi-Apnimed Sleep Science for $100 mln from Apni...
Shionogi & Co Ltd - to acquire 50% stake in Shionogi-Apnimed Sleep Science for $100 mln from Apnimed Inc marketscreener.com
Shionogi & Co: Strong revenue and profit growth, boosted by acquisitions and robust royalty incom...
Shionogi & Co: Strong revenue and profit growth, boosted by acquisitions and robust royalty income TradingView
Shionogi Expands Rare Disease Portfolio With $2.5bn Radicava Buy From Tanabe - Citeline News & In...
Shionogi Expands Rare Disease Portfolio With $2.5bn Radicava Buy From Tanabe Citeline News & Insights
Shionogi & Co., Ltd.: - marketscreener.com
Shionogi & Co., Ltd.: marketscreener.com
Shionogi & Co., Ltd. entered into an equity transfer agreement to acquire 50% remaining stake in ...
Shionogi & Co., Ltd. entered into an equity transfer agreement to acquire 50% remaining stake in Shionogi-Apnimed Sleep Science, LLC from Apnimed, Inc. for $150 million. marketscreener.com
Japan’s Shionogi boosts ViiV stake in $2.13 billion deal as Pfizer exits - WTVB
Japan’s Shionogi boosts ViiV stake in $2.13 billion deal as Pfizer exits WTVB
Yomiuri: Nobel Prize Winner, Shionogi Jointly Developing New Cancer Drug - MarketWatch
Yomiuri: Nobel Prize Winner, Shionogi Jointly Developing New Cancer Drug MarketWatch
FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 F...
FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure Business Wire
We’re reading about the first approved GLP-1 pill, deal-hungry Ipsen, and more - statnews.com
We’re reading about the first approved GLP-1 pill, deal-hungry Ipsen, and more statnews.com
GSK to retain majority stake in ViiV Healthcare as Pfizer exits and Shionogi increases share - In...
GSK to retain majority stake in ViiV Healthcare as Pfizer exits and Shionogi increases share Investing.com
IDWeek 2025: Shionogi Presents Real-World and Surveillance Data Reinforcing Role of Cefiderocol A...
Shionogi strikes research and option deal with BioVersys for antibacterial assets - FirstWord Pharma
Shionogi strikes research and option deal with BioVersys for antibacterial assets FirstWord Pharma
GSK, Pfizer and Shionogi finalize changes to ViiV Healthcare ownership By Investing.com - Investi...
GSK, Pfizer and Shionogi finalize changes to ViiV Healthcare ownership By Investing.com Investing.com South Africa
BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculou...
Shionogi Delivers Double-Digit Profit Growth and Confirms FY2026 Outlook - The Globe and Mail
Shionogi Delivers Double-Digit Profit Growth and Confirms FY2026 Outlook The Globe and Mail
GSK and Shionogi agree to replace Pfizer's stake in ViiV Healthcare - BioSpectrum Asia
GSK and Shionogi agree to replace Pfizer's stake in ViiV Healthcare BioSpectrum Asia
Shionogi expands rare disease presence with acquisition of global rights to Tanabe's RADICAVA for...
Shionogi expands rare disease presence with acquisition of global rights to Tanabe's RADICAVA for $2.5 B BioSpectrum Asia
Shionogi Advances S-531011 Cancer Trial, Keeping Long-Term Upside in Play for SGIOF Investors - T...
Shionogi Advances S-531011 Cancer Trial, Keeping Long-Term Upside in Play for SGIOF Investors TipRanks
BioVersys and Shionogi agree to develop ansamycin leads - Pharmaceutical Technology
BioVersys and Shionogi agree to develop ansamycin leads Pharmaceutical Technology
Shionogi puts more than $600M on the table for Swiss biotech's antibiotic program - fiercebiotech...
Shionogi puts more than $600M on the table for Swiss biotech's antibiotic program fiercebiotech.com
Shionogi Lifts Profit Outlook on HIV Royalties, Overseas Growth - Bloomberg.com
Shionogi Lifts Profit Outlook on HIV Royalties, Overseas Growth Bloomberg.com
Shionogi to increase stake in ViiV Healthcare as Pfizer exits - Investing.com
Shionogi to increase stake in ViiV Healthcare as Pfizer exits Investing.com
Lupin Acquires Branded Product Portfolio from Shionogi in Japan - Lupin | Press Release - lupin.com
Lupin Acquires Branded Product Portfolio from Shionogi in Japan - Lupin | Press Release lupin.com
Pfizer to Exit ViiV Healthcare as GSK and Shionogi Reshape Ownership - Finviz
Pfizer to Exit ViiV Healthcare as GSK and Shionogi Reshape Ownership Finviz
Pfizer to depart GSK’s ViiV as Shionogi doubles its stake - Endpoints News
Pfizer to depart GSK’s ViiV as Shionogi doubles its stake Endpoints News
Shionogi & Co. Hits Day High with Strong Intraday Performance, Up 4.55% - Markets Mojo
Shionogi & Co. Hits Day High with Strong Intraday Performance, Up 4.55% Markets Mojo
Global pharmaceutical company Shionogi joins Paddington Life Sciences Partners - Imperial College...
Global pharmaceutical company Shionogi joins Paddington Life Sciences Partners Imperial College Healthcare NHS Trust
Accelerating drug discovery with AI innovation - SAS: Data and AI Solutions
Accelerating drug discovery with AI innovation SAS: Data and AI Solutions
Shionogi inks hearing loss deal with Salubritas Therapeutics - thepharmaletter.com
Shionogi inks hearing loss deal with Salubritas Therapeutics thepharmaletter.com